New diabetes drug DA-5218 aims to lower blood sugar in patients not helped by metformin
NCT ID NCT07229534
First seen Nov 17, 2025 · Last updated May 17, 2026 · Updated 18 times
Summary
This study tests a new medicine called DA-5218 for people with type 2 diabetes whose blood sugar is not well controlled with metformin alone. About 238 adults will receive either DA-5218 or an active comparator to see how well it lowers HbA1c (a measure of blood sugar over time) and whether it is safe. The trial is double-blind, meaning neither participants nor doctors know who gets which treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.